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The  Act  of  12  May  2011  on the  Reimbursement  of Medicines,  Foodstuffs  Intended  for  Partic-
ular  Nutritional  Uses  and  Medical  Devices  constitutes  a major  change  of  the  reimbursement
policy  in  Poland.  The  main  aims  of  this  Act  were  to rationalize  the  reimbursement  policy  and
to reduce  spending  on reimbursed  drugs.  The  Act  seems  to have  met  these  goals:  reimburse-
ment  policy  (including  pricing  of reimbursed  drugs)  was  overhauled  and  the expenditure
of  the  National  Health  Fund  on  reimbursed  drugs  saw  a significant  decrease  in the  year
following  the  Act’s  introduction.  The  annual  savings  achieved  since  then  (mainly  due to the
introduction  of  risk  sharing  schemes),  have  made  it possible  to include  new  drugs  into  the
reimbursement  list  and  improve  access  to innovative  drugs.  However,  at  the  same  time,  the
decrease  in  prices  of reimbursed  drugs,  that  the  Act  brought  about,  led  to an  uncontrolled
outflow  of some  of  these  drugs  abroad  and  shortages  in Poland.  This  paper  analyses  the
main  changes  introduced  by  the  Reimbursement  Act  and their  implications.  Since  the  Act
came into  force  relatively  recently,  its full impact  on  the  reimbursement  policy  is not  yet
possible  to assess.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
There is no homogeneous reimbursement policy in the
European Union (EU). EU Member States are free to set their
own lists of reimbursed drugs, their prices and reimburse-
ment levels, as long as they comply with the overall EU
regulations, such as the Transparency Directive [1,2]. The
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growth in public pharmaceutical expenditure (76% in the
outpatient sector in the EU countries on average between
2000 and 2009) forced many European countries to intro-
duce new pricing and reimbursement regulations aimed
at reducing spending on drugs [2]. In Poland, spending
on drug reimbursement by the public payer, the National
Health Fund (NHF), saw a 12% growth in 2009 compared
to 2008, which was the highest annual growth rate in the
2000–2011 period [3].
The Act on the Reimbursement of Medicines, Food-
stuffs Intended for Particular Nutritional Uses and Medical
Devices [4] (hereinafter referred to as “the Reimbursement
Act” or “the Act”) was  drafted by the Ministry of Health
in order to rationalize the activity of the NHF in the field
is is an open access article under the CC BY-NC-ND license
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f reimbursement policy and to rationalize its budget (i.e.
educe its spending on reimbursed drugs). Another objec-
ive was to make prices of reimbursed drugs uniform across
he country by introducing fixed prices and fixed wholesale
nd retail margins and to implement a new way of calcu-
ating them, which would comply with the EU accounting
tandards (Commission Regulation (EC) No 1126/2008 of 3
ovember 2008) and EU transparency regulations (mainly
ouncil Directive 89/105/EEC of 21 December 1988 relat-
ng to the transparency of measures regulating the prices
f medicinal products for human use and their inclusion in
he scope of national health insurance systems [5] which
ecommends that reimbursement decisions are made on
he basis of a credible assessment of data from the best
vailable clinical trials and an assessment of clinical effec-
iveness and allows for experts’ opinions to be additionally
aken into account).
. Policy content and process
The Reimbursement Act came into force on 1 January
012 as part of a package of healthcare acts that also
ncluded: the Act on the Information Systems in Health
are, the Act on Patient Rights and the Patient Rights
mbudsman, the Act on the Professions of Physician and
entist, and the Act on Therapeutic Activity. It laid down, in
ne legal act, the rules for the reimbursement of medicines,
oodstuffs intended for particular nutritional uses, and
edical devices. The key changes introduced by this Act
re summarized in Table 1.
.1. Pharmaceutical cost containment measures
In order to alleviate budgetary pressures, the Act
ntroduced several mechanisms to decrease expenditure
n reimbursed drugs: (1) the Act defined a percentage of
he total funds for guaranteed benefits that can be used
or drug reimbursement–this percentage was set at 17% (it
sed to be 18% or more); (2) when the amount spent on
rug reimbursement exceeds 17%, all Marketing Authori-
ation Holders (MAHs) of the reimbursed drugs will have
o cover the extra expenditure (a pay-back mechanism);
3) the Act made statutory prices based on mandatory
egotiations, set price limits for generic drugs (set at 75%
f the original drug price) and introduced adjusted fixed
holesale and retail margins (the pricing process for reim-
ursed drugs is depicted in Fig. 1). Before the introduction
f the Act, there were no fixed prices for reimbursed drugs,
hich meant that access to reimbursed drugs was unequal.
rices had a character of maximum prices and pharmacies
ould charge lower prices to attract customers and increase
ales. Pricing of generics was not regulated. The wholesale
argin was relatively high compared to other European
ountries (8.91% in Poland compared to less than 5% in
he Czech Republic, Greece, Spain, Finland, Italy, Sweden,
nd Latvia [6]) but manufacturers could offer rebates
o pharmacies and this practice was widespread. There
ere also no fixed retail margins. The Reimbursement Act
rought the wholesale margin down to 5% (from 2014
nwards), prohibited the use of rebates (pharmacies may
ow face financial penalties if they obtain rebates from the 120 (2016) 356–361 357
manufacturers), and made retail margin dependent on the
wholesale price. The Act also prohibited advertising and
other marketing of reimbursed drugs, which was  previ-
ously not restricted (Table 1).
Another improvement introduced by the Reimburse-
ment Act was the establishment of the Economic
Committee, which is attached to the Ministry of Health and
is responsible for negotiating with pharmaceutical compa-
nies the official sales prices for reimbursed drugs, levels
of patient co-payments, and indications for reimburse-
ment. The Economic Committee makes recommendations
regarding: (1) the level of reimbursement (this can either
be (a) 100% reimbursement with no patient co-payment,
i.e. free of charge; (b) a flat fee; or (c) partial reimburse-
ment – 70% or 50%), depending on the cost and duration
of treatment; (2) differences in the reimbursement level,
e.g. lower drug prices for certain population groups; and
(3) reimbursement period (2, 3 or 5 years). According to the
Act, reimbursement decision has to be made on the basis of
scientific evidence. To have the drug reimbursed, the MAH
has to prove its cost-effectiveness compared to the alter-
native therapeutic substance which is already reimbursed
from public funds.
Another novelty of the Act in the area of reimbursement
is the introduction of a negative reimbursement criterion,
whereby reimbursement is waived when a health condi-
tion can be avoided by a change in lifestyle. This can lead
to the exclusion of certain drugs, which could improve the
quality of life for the patients, from reimbursement.
Under the provision of the Act, physicians were given
additional obligations in terms of writing detailed pre-
scriptions for reimbursed drugs, including specifying the
reimbursement category. The NHF may  impose heavy
financial penalties if irregularities in prescribing (e.g.
wrong level of reimbursement indicated on the prescrip-
tion or writing a prescription for a reimbursed drug to a
person not entitled for reimbursement) are detected.
2.2. Access to innovative high-cost drugs
The Reimbursement Act also introduced risk-sharing
schemes (RSSs), which constitute a relatively novel mecha-
nism for financing innovative medicines that are high-cost
[7]. RSSs are mostly used when there is uncertainty about
the cost-effectiveness of expensive, innovative drugs. Dur-
ing the health technology assessment (HTA) process a
“threshold price” is calculated, i.e. the price at which the
Incremental Cost-Effectiveness/Utility Ratio (ICER/ICUR)
(the result of Cost-Effectiveness/Utility Analysis) does not
exceed the threshold of three times per capita GDP. The
MAH  of the expensive drug may  reduce the ICER/ICUR by
proposing a risk-sharing scheme (RSS). It allows the dis-
tribution of financial and/or health outcomes risk between
the MAH  and the public payer [7]. In accordance with the
Reimbursement Act [4] the proposed RSSs can (1) make
the MAH’s revenue dependent on the health outcomes (i.e.
focus on the health effects); (2) make the official sales
price dependent on the MAH  assuring the supply of the
drug at lower negotiated price (price discount); (3) make
the official sales price dependent on the drug’s turnover
(price-volume agreement); (4) make the official sales price
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Table 1
Reimbursement policy before and after 1 January 2012.
2004–2011 From 2012
Governance and regulation
Key legal acts Act of 27 August 2004 on Healthcare
Services Financed from Public Sources
and the Act of 5 May  2001 on Pricing
Act of 12 May  2011 on the Reimbursement of
Medicines, Foodstuffs Intended for Particular
Nutritional Uses and Medical Devices
Rules, conditions, and procedures for administrative decision making in the area of drug reimbursement
Advisory body to the Ministry of Health Drug Economy Task Force* Economic Committee**
Decision-making and advisory body at
the Agency for Health Technology
Assessment
Consultative Council Transparency Council for the President of the Agency
for Health Technology Assessment***
Rules for assigning drugs to the particular reimbursement category
Reimbursement limit groups
(internal reference pricing)
Not used Medicine with the same international name or
different international name but with similar
therapeutic effect and similar mechanism of action,
with the same reimbursement indications and similar
clinical effectiveness belong to the same limit group
Rules  and procedures for setting the official sales prices for reimbursed drugs
Prices of reimbursed drugs Maximum prices; pharmacies can sell
drugs at lower prices
Fixed prices; the same prices apply to all pharmacies
Prices of generic drugs Not regulated First generic drug on the list: 75% of original drug
price; second and next generic drug on the list: price
equal to the price of the cheapest medicine with the
same active substance
Wholesale margin 8.91% 7% in 2012
6% in 2013
5% since 2014
Retail margin Depends solely on the price of the drug Calculated on the wholesale price of the product, being
the basis for the limit in a given limit group
Publication of reimbursement list Once or twice a year (irregularly);
published as a regulation
Every 2 months; published as an announcement
Other cost containment measures
Individual price agreements Not used Statutory prices are based on mandatory negotiations
Risk-sharing schemes (RSSs) Not used Yes; it is a mechanism which is used for financing
innovative medicines that are high-cost and allows the
distribution of financial and/or health outcomes risk
between the Marketing Authorisation Holders (MAH)
and the public payer
Percentage of the total funds for
guaranteed benefits designed for
drug reimbursement
18% or more 17%
Pay-back mechanisms Not used If the total amount spent on drug reimbursement
exceeds 17%, all MAHs  of the reimbursed drugs must
cover the difference (excluding reimbursed drugs for
which a RSS was agreed between the Ministry of
Health and MAH)
Source: Authors’ own  compilation based on the legal acts cited in the Table.
* Consists of 3 representatives of the Ministry of Health, 3 representatives of the Ministry of Finance, 3 representatives of the Ministry of Economy.
** ntatives
, 2 repre
dical DeConsists of 12 representatives of the Ministry of Health and 5 represe
*** Consists of 10 HTA experts, 4 representatives of the Ministry of Health
of  the President of the Office for Registration of Medicinal Products, Me
Patients’ Rights.
dependent on the MAH  returning part of the reimburse-
ment amount to the public payer (pay-back agreement); (5)
set other reimbursement conditions which would increase
access to the publicly guaranteed benefits or decrease their
costs.The Minister of Health recognizes the value of the RSSs
and has been trying to incentivize pharmaceutical com-
panies to enter into such schemes by offering them an
exemption from the general payback scheme if they engage of the President of the National Health Fund.
sentatives of the President of the National Health Fund, 2 representatives
vices and Biocidal Products, 2 representatives of the Commissioner for
in RSSs instead. At the same time, companies may  be fined
by the Minister of Health if the agreed risk-sharing condi-
tions are not met  [7].
Apart from the RSSs, another mechanism aimed at
increasing access to medicines is the mandatory bi-
monthly reviews of the reimbursement lists. Before the
introduction of the Act, reimbursement lists were updated
irregularly, at most once or twice a year, which limited the
timely introduction of new drugs.
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by EUR 481 million compared to 2011 (a decrease of
22%) (Fig. 2) [1]. Since then, expenditure on ambula-
tory drugs has been growing at about 4.5–5.5% per year,
which is slightly higher than the growth rates observed in
2010–2011 (3.6–3.7%). Before 2010, growth in spending on
ambulatory drugs fluctuated highly from 0.6% in 2007 to
12% in 2009.
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The similar trend was observed in total NHF expen-
diture on the reimbursement of drugs, which decreased
by EUR 438 million in 2012 (17%) compared to 2011. In
2013 and 2014, while increasing, total drug expenditure
remained lower than the 2011 level (by EUR 339 million
and EUR 74 million, respectively). Total spending on the
reimbursed drugs grew by about 4.5% in 2013 and 11.5% in
2014. This means that the reduction in spending on reim-
bursed drugs was largely a one-off effect. This may  be in
part explained by the increased spending on therapeutic
drug programmes (see below) and by the fact that the num-
ber of drugs reimbursed from the public funds in Poland
has continued to grow. Between January 2012 and end of
June 2014, 29 new original and 7 generic therapeutic sub-
stances were added to the reimbursement list [8]. Another
11 substances that had been available within a customized
chemotherapy were also added to the reimbursement list.
The number of items on the reimbursement list for ambu-
latory medicines increased from 2695 in January 2012 to
3743 in May  2015 [8].
The NHF also benefited from the introduction of the RSSs
[3], although it is difficult to quantify these benefits as data
on RSSs is not publicly available (neither the NHF nor the
Ministry of Health publish such data in Poland and such
data is also not available for other countries [7]). According
to estimates by INFARMA (Employers’ Associations of Inno-
vative Pharmaceutical Companies), in 2012 and 2013, the
total amount received by the NHF under the RSSs was EUR
76 million, which is much higher than the expenditure on
reimbursing new innovative therapeutic substances that
were added to the reimbursement list in those years which,
according to the same source, amounted to EUR 3.4 million
in 2012 and EUR 28.8 million in 2013 [9].
3.1.2. Effects on the patients
The implementation of the Reimbursement Act resulted
in a significant decrease of the average retail price of reim-
bursed drugs and the average reimbursement limit. The
latter means a higher level of patient co-payments, while
the former has the opposite effect on the level of patient
co-payments. In 2013, the level of patient co-payments for
the reimbursed drugs was higher by EUR 0.04 compared
to 2010. Between 2013 and 2014, the average patient co-
payment decreased by EUR 0.18 compared to 2010, which
means that reimbursed drugs have become more afford-
able to the patients in recent years [9]. In May  2015 the
average level of co-payment was EUR 3.19, compared to
EUR 3.68 in January 2012, i.e. a decrease of 24% [8]. How-
ever, the prices of non-reimbursed prescription drugs are
still growing as does the overall amount of patient expen-
diture on drugs (for both reimbursed and non-reimbursed
prescription drugs).
The Reimbursement Act also introduced substantial
changes in the field of specialized therapies (mainly for
oncology and severe chronic diseases). In 2012 and 2013,
the NHF increased its expenditure on therapeutic drug
programmes. Total NHF expenditure on medications used
in therapeutic programmes or in chemotherapy increased
by about 36% between 2012 and 2014 [3]. The number
of patients treated within the existing therapeutic pro-
grammes increased from about 55,000 people (excluding 120 (2016) 356–361
customized chemotherapy) in 2011 to about 64,000 in
2013. In addition, 5000 people were treated under 13 new
therapeutic programmes. At the same time, the number of
patients covered by customized chemotherapy decreased
[8,9].
Patients are also likely to have benefited from better
access to innovative drugs and to drugs in general. This is
mainly thanks to the RSSs, but also thanks to the more fre-
quent updates of reimbursement lists (bi-monthly) and the
introduction of penalties for pharmacies in case of failure
to ensure the continuity of supply of reimbursed drugs.
The introduction of fixed official prices and margins for
reimbursed drugs resulted in a reduction of their prices,
and, as a consequence, Poland is one of EU countries
with the cheapest drugs [9]. This caused outflow of drugs
to other EU countries and shortages in Poland: phar-
macies buy drugs from wholesalers or manufacturers at
prices valid in Poland and sell them (via distributors)
in Western European countries instead of selling them
in Poland, as this is much more profitable. According to
estimates, some 200 medications are missing, including
insulin, anticoagulants, and drugs for Parkinson disease,
cancer, and pulmonary diseases [10]. This parallel trade in
reimbursed drugs is illegal and is prohibited under EU’s
directive on pharmaceutical trading (trade in other, i.e.
non-reimbursed, drugs is allowed). This situation resulted
in an ongoing protest of pharmacists who  insist on guaran-
teeing equal access to reimbursed drugs [10].
3.1.3. Effects on the physicians, pharmacies and
manufacturers
The effects on the other stakeholders are not well
known. Physicians are likely to prescribe reimbursed drugs
with greater caution and accuracy. Pharmacists are obliged
to verify prescriptions and, in case of any concerns, must
contact the supervisory bodies, i.e. the Main Pharmaceuti-
cal Inspectorate, and the NHF [1]. The profits of pharmacies
and pharmaceutical companies are expected to decrease,
following the introduction of fixed prices and margins, but
to date there has been no reliable data allowing to verify
this. The introduction of some expensive, innovative drugs
to the reimbursement list by the NHF has the opposite
effect and the total effect on the manufacturers’ profits is
difficult to gauge. The prohibition of advertising and other
marketing of reimbursed drugs poses threat to the exist-
ence of smaller pharmacies. This may  mean poorer access
to drugs if these pharmacies are closed, but so far there is
no evidence in this area.
3.2. Effects on pharmaceutical regulation
One of the undesired effects of the price reductions
resulting from the Reimbursement Act, was  the outflow
of drugs abroad and their shortages on the Polish market
(see Section 3.1). This motivated the government to take
action. The amendment of the Act on Pharmaceutical Law,
signed by the President on 21 May  2015, will significantly
tighten the monitoring of drug availability and their export
to other countries [8]:
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wholesalers and pharmacies will be obliged to inform the
Main Pharmaceutical Inspectorate about the availability
of drugs;
based on the above information, the Minister of Health
will publish the list of drugs that are likely to become
unavailable in Poland;
pharmacists will be obliged to inform the Main Phar-
maceutical Inspector (within 24 h) about the lack of a
reimbursed drug;
the wholesaler that wants to export a drug with poten-
tially limited availability will be obliged to inform the
Main Pharmaceutical Inspectorate; the latter will have
30 days to object this;
any refusal to order drugs will have to be justified by the
wholesaler.
. Conclusions
The implementation of the Reimbursement Act brought
bout numerous changes that affected the entire health
are sector, including patients, physicians, pharmacists,
ublic officials, and pharmacists.
The key effects were the economic benefits to the NHF
lower expenditure on reimbursed drugs) and patients
lower average spending on reimbursed drugs, though
o-payments for certain drugs may  be higher and the
verage spending on prescription drugs is higher [3], [8]).
atients also benefit from enhanced availability of new
rugs but also suffer from shortages of certain drugs due
o (illegal) reverse chain of drug distribution, which is
he key unintended consequence of the Reimbursement
ct. Medium and long-term effects of the Act on the
xpenditure on reimbursed drugs by both the NHF and
he patients and on the access to drugs remain to be
een.
[
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